A Phase 2B, randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 Compared to Chemotherapy or to CRS-207 Alone in Adults with Previously-Treated Metastatic Pancreatic Adenocarcinoma
ID Number 14-0658Principal Investigator(s)
Max W Sung
Department(s) or Division(s)
Hematology and Medical Oncology
A vaccine is something that is given to boost a person's immune system to fight or protect against disease. The purpose of this study is to test whether GVAX pancreas vaccine and CRS-207, a weakened form of Listeria bacteria that has been modified to reduce the likelihood that it will cause disease, together are safe and work better than chemotherapy to treat patients with advanced pancreatic cancer who have received at least two prior chemotherapy treatment regimens for metastatic cancer (cancer that has spread beyond the pancreas). A small number of patients who have received one prior chemotherapy regimen will also be included.
Recruiting Patients: No